Through the nationwide network all patients in Germany with advanced lung cancer have access to molecular diagnostics and innovative therapies. Since 2018, selected network centers have joined forces in the “National Network Genomic Medicine (nNGM) Lung Cancer” – including all oncological leading centers funded by the German Cancer Aid. The nNGM is an advancement of the Cologne Network Genomic Medicine, which has been successfully advocating for the implementation of personalized therapies in routine care for lung cancer patients since 2010. In the nationwide network, patients with advanced lung cancer have access to state-of-the-art molecular diagnostics and the latest therapies, including within the framework of clinical trials.
The German Cancer Aid has been supporting this collaborative project since April 1, 2018.
